Novo Nordisk

Learn why Timothy chose this once-weekly Factor 9 therapy.

Used to treat, prevent, or reduce the number of bleeding episodes in people with hemophilia B.
See full indication below.

A man named Timothy sits at the piano and smiles.

“Hi, I’m Timothy”

I live with severe hemophilia B and I’m proud to be an advocate for our community. My wife and I are recent empty-nesters, and these days I’m focused on enjoying all life has to offer.

I spend my time volunteering and traveling, but my previous hemophilia treatment just wasn’t keeping up with my active lifestyle.

After doing my own research and discussing it with my doctor, I made the switch to once-weekly Rebinyn^® to help manage my hemophilia B.

Watch My Story

Scroll to meet your Hemophilia Community Liaison.

Selected Important Safety Information

What is the most important information I need to know about Rebinyn^®?

•	Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn^®.

Who should not use Rebinyn^®?
Do not use Rebinyn^® if you:

•	are allergic to Factor IX or any of the other ingredients of Rebinyn^®.

•	are allergic to hamster proteins.

Please click here or scroll below for additional Important Safety Information.

One-to-one support, every step of the way.

Novo Nordisk Hemophilia Community Liaisons—known as HCLs—are available to answer your questions about Rebinyn^®. Experienced and active in the hemophilia community, HCLs can provide you with resources to help manage your bleeding disorder.

Connect with an HCL

Indications and Usage

What is Rebinyn^®, Coagulation Factor IX (Recombinant), GlycoPEGylated?

Rebinyn^® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn^® is used to treat, prevent, or reduce the frequency (number) of bleeding episodes in people with hemophilia B. Your healthcare provider may give you Rebinyn^® when you have surgery. Rebinyn^® is not used for immune tolerance therapy.

Important Safety Information

What is the most important information I need to know about Rebinyn^®?

•	Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn^®.

Who should not use Rebinyn^®?

Do not use Rebinyn^® if you:

•	are allergic to Factor IX or any of the other ingredients of Rebinyn^®.
•	are allergic to hamster proteins.

What should I tell my healthcare provider before using Rebinyn^®?

Tell your healthcare provider if you:

•	have or have had any medical conditions.
•	take any medicines, including non-prescription medicines and dietary supplements.
•	are nursing, pregnant, or plan to become pregnant.
•	have been told you have inhibitors to Factor IX.

How should I use Rebinyn^®?

•	Rebinyn^® is given as an infusion into the vein.
•	Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn^®.
•	Do not stop using Rebinyn^® without consulting your healthcare provider.

What are the possible side effects of Rebinyn^®?

•	Common side effects include infusion site reaction (bruising, bleeding, swelling, pain, or redness), itching, and rash.
•	Your body can also make antibodies called “inhibitors” against Factor IX, including Rebinyn^®, which may stop Rebinyn^® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.
•	Call your healthcare provider right away or get emergency treatment right away if you get, for example, any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
•	You may be at an increased risk of forming blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness, or swelling.
•	Animals given repeat doses of Rebinyn^® showed Polyethylene Glycol (PEG) in certain cells in the brain. The potential human implications of these animal tests are unknown.

Please click here for Prescribing Information.

Rebinyn^® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.